1,3,thiazolinyl and 1,3 thiazinyl substituted indolinones

Claim 2

A compound having the formula ##STR59## wherein R 2 is hydrogen, and the radical ##STR60## represents a 5- or 6-membered ring containing three or four carbons and one double bond; and pharmaceutically acceptable acid-addition salts thereof.

Claim 3

A compound as defined in claim 1 having the name 1-(2-thiazolin-2-yl)-2-indolinone.

Claim 4

A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable carrier therefor.

Claim 5

A method of treating inflammation in mammalian species, which comprises orally administering to a mammalian host a therapeutic amount of a composition as defined in claim 3.

Claim 6

A compound having the formula ##STR61## wherein R 2 is selected from the group consisting of hydrogen, lower alkyl, phenyl or lower alkylphenyl; R 3 is selected from the group consisting of hydrogen, lower alkyl, trifluoromethyl, halo, lower alkoxy, nitro, cyano, amino, di-lower alkylamino or ##STR62## wherein R contains less than 11 carbons and is selected from the group consisting of lower alkyl, lower alkenyl, phenyl, phenyl-lower alkyl, cycloakyl, cycloalkenyl, cycloalkyl-lower alkyl, and cyclo-lower alkenyl, however where n is 2, and adjacent R 3 groups are present, at least one of the R 3 groups is other than t-butyl, trifluoromethyl or nitro; aryl is phenyl or phenyl mono-substituted with a member selected from the group consisting of halogen, lower alkyl, nitro, trifluoromethyl, and lower alkoxy; n is 1 or 2; the radical ##STR63## represents a 5- or 6-membered ring having three or four carbons and one double bond; and pharmaceutically acceptable acid-addition salts thereof.

Claim 7

A compound having the formula ##STR61## wherein R 2 is selected from the group consisting of hydrogen, lower alkyl, phenyl or lower alkylphenyl; R 3 is selected from the group consisting of hydrogen, lower alkyl, trifluoromethyl, halo, lower alkoxy, nitro, cyano, amino, di-lower alkylamino or ##STR62## wherein R contains less than 11 carbons and is selected from the group consisting of lower alkyl, lower alkenyl, phenyl, phenyl-lower alkyl, cycloakyl, cycloalkenyl, cycloalkyl-lower alkyl, and cyclo-lower alkenyl, however where n is 2, and adjacent R 3 groups are present, at least one of the R 3 groups is other than t-butyl, trifluoromethyl or nitro; aryl is phenyl or phenyl mono-substituted with a member selected from the group consisting of halogen, lower alkyl, nitro, trifluoromethyl, and lower alkoxy; n is 1 or 2; the radical ##STR63## represents a 5- or 6-membered ring having three or four carbons and one double bond; and pharmaceutically acceptable acid-addition salts thereof.

Claim 8

A compound as defined in claim 5 having the formula ##STR64##

Claim 9

A compound as defined in claim 5 having the formula ##STR65##

Claim 10

A compound as defined in claim 5 wherein n is 1.

Claim 11

A compound as defined in claim 5 wherein n is 2.

Claim 12

A compound as defined in claim 7 wherein R 3 is H, --CH 2 aryl is --CH 2 C 6 H 5 and ##STR66##

Claim 13

A compound as defined in claim 6 wherein R 3 is H, and ##STR67##

Claim 14

A compound as defined in claim 1 wherein R 1 is selected from the group consisting of ##STR68## R 3 is selected from the group consisting of H, halo, and lower alkyl, R 4 is selected from the group consisting of H, ##STR69## and R 5 is selected from the group consisting of H and --CH 2 C 6 H 5 .

Claim 15

A compound as defined in claim 5 having the name 1,3-bis(2-thiazolin-2-yl)-2-indolinone.

Claim 16

A compound as defined in claim 5 having the name 1,3-bis(4,5-dihydro-2-thiazolyl)-1,3-dihydro-3- (phenylmethyl)-2H-indol-2-one.

Claim 17

A pharmaceutical composition comprising a compound as defined in claim 5 and a pharmaceutically acceptable carrier therefor.

Claim 18

A method of treating inflammation in mammalian species, which comprises orally administering to a mammalian host a therapeutic amount of a composition as defined in claim 15.